Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.

De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P, Di Marzo V.

Br J Pharmacol. 2013 Jan;168(1):79-102. doi: 10.1111/j.1476-5381.2012.02027.x.

2.

Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.

Wang Y, Liu G, Tong D, Parmar H, Hasenmayer D, Yuan W, Zhang D, Jiang J.

Prostate. 2015 Aug 1;75(11):1187-96. doi: 10.1002/pros.23000. Epub 2015 Apr 20.

PMID:
25894097
3.

Towards the use of non-psychoactive cannabinoids for prostate cancer.

Pacher P.

Br J Pharmacol. 2013 Jan;168(1):76-8. doi: 10.1111/j.1476-5381.2012.02121.x.

4.

Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.

Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS.

Prostate. 2012 Jun 1;72(8):875-85. doi: 10.1002/pros.21490. Epub 2011 Oct 5.

PMID:
22072572
5.

Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.

Quéro L, Giocanti N, Hennequin C, Favaudon V.

Prostate. 2010 Mar 1;70(4):401-11. doi: 10.1002/pros.21074.

PMID:
19902473
6.

Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.

Zhang Y, Won SH, Jiang C, Lee HJ, Jeong SJ, Lee EO, Zhang J, Ye M, Kim SH, Lü J.

Pharm Res. 2012 Jun;29(6):1595-608. doi: 10.1007/s11095-012-0670-3. Epub 2012 Jan 27.

PMID:
22281759
7.

Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.

Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.

Br J Cancer. 1999 Sep;81(2):242-51.

8.

Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.

Madarová J, Lukesová M, Hlobilková A, Riháková P, Murray PG, Student V, Vojtsek B, Kolár Z.

Neoplasma. 2001;48(5):419-24.

PMID:
11845989
9.

5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.

Gravina GL, Marampon F, Di Staso M, Bonfili P, Vitturini A, Jannini EA, Pestell RG, Tombolini V, Festuccia C.

Prostate. 2010 Aug;70(11):1166-78. doi: 10.1002/pros.21151.

PMID:
20333699
10.

Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer.

Danquah M, Duke CB 3rd, Patil R, Miller DD, Mahato RI.

Pharm Res. 2012 Aug;29(8):2079-91. doi: 10.1007/s11095-012-0737-1. Epub 2012 Mar 27.

PMID:
22451249
11.

Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.

Dondoo TO, Fukumori T, Daizumoto K, Fukawa T, Kohzuki M, Kowada M, Kusuhara Y, Mori H, Nakatsuji H, Takahashi M, Kanayama HO.

Anticancer Res. 2017 Jan;37(1):125-134.

PMID:
28011482
12.

Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.

Murthy S, Agoulnik IU, Weigel NL.

Prostate. 2005 Sep 1;64(4):362-72.

PMID:
15754350
13.

Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.

De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, Stott CG, Di Marzo V.

Br J Pharmacol. 2011 Aug;163(7):1479-94. doi: 10.1111/j.1476-5381.2010.01166.x.

14.

Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.

Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M.

Prostate. 2008 May 15;68(7):793-801. doi: 10.1002/pros.20748.

PMID:
18324645
15.

Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.

Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, Lin CY, Huo C, Su LC, Liao S.

Cancer Sci. 2011 Nov;102(11):2022-8. doi: 10.1111/j.1349-7006.2011.02043.x. Epub 2011 Aug 18. Erratum in: Cancer Sci. 2013 Jan;104(1):142. Huo, Chiech [corrected to Huo, Chieh].

16.

Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.

Kawata H, Arai S, Nakagawa T, Ishikura N, Nishimoto A, Yoshino H, Shiraishi T, Tachibana K, Nakamura R, Sato H.

Prostate. 2011 Sep;71(12):1344-56. doi: 10.1002/pros.21351. Epub 2011 Feb 9.

PMID:
21308717
17.

Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.

Landriscina M, Bagalà C, Piscazzi A, Schinzari G, Quirino M, Fabiano A, Bianchetti S, Cassano A, Sica G, Barone C.

Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.

PMID:
19152342
18.

Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?

Bennett HL, Stockley J, Fleming JT, Mandal R, O'Prey J, Ryan KM, Robson CN, Leung HY.

BJU Int. 2013 Apr;111(4):672-82. doi: 10.1111/j.1464-410X.2012.11409.x. Epub 2012 Aug 16.

19.

Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance.

Browne G, Nesbitt H, Ming L, Stein GS, Lian JB, McKeown SR, Worthington J.

Br J Cancer. 2012 Nov 6;107(10):1714-21. doi: 10.1038/bjc.2012.455. Epub 2012 Oct 16.

20.

Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.

Yan J, Xie B, Capodice JL, Katz AE.

Prostate. 2012 Feb;72(3):244-52. doi: 10.1002/pros.21426. Epub 2011 Jun 8.

PMID:
21656835

Supplemental Content

Support Center